Yahoo · Sep 4, 2026
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
NYSE · DHR
Danaher Corporation
Healthcare · Medical - Diagnostics & Research
$211.03
Down-$3.54 (-1.68%)
Updated Sep 4, 2026, 5:00 PM
SID Score
6.1/10
Composite research score
Smart Money
51/100
Neutral
- Market cap
- 166.5B
- P/E ratio
- 47.14
- Dividend yield
- 0.58%
- 52-week range
- $160.93 – $242.80
- Volume
- 2.42M
- Avg. volume
- 4.18M
Price performance
DHR price history
1M range · 21 trading sessions · Daily adjusted prices
DHR closed at $211.03 after 21 trading sessions, up 5.53% for the selected period.
- Last close
- $211.03
- Period change
- +5.53%
- Period low
- $199.58
- Period high
- $218.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $210.51 | $213.13 | $206.05 | $211.03 | 2.42M |
| Sep 2, 2026 | $207.77 | $212.7793 | $206.10 | $209.91 | 2.95M |
| Sep 1, 2026 | $214.74 | $215.00 | $206.55 | $206.93 | 3.15M |
| Aug 31, 2026 | $213.45 | $215.385 | $212.22 | $213.56 | 3.61M |
| Aug 28, 2026 | $215.10 | $217.04 | $212.8502 | $216.07 | 2.86M |
| Aug 27, 2026 | $214.78 | $218.57 | $213.092 | $215.68 | 2.93M |
| Aug 26, 2026 | $213.23 | $216.8499 | $212.81 | $215.36 | 2.53M |
| Aug 25, 2026 | $213.88 | $216.77 | $212.24 | $215.97 | 2.34M |
| Aug 24, 2026 | $218.33 | $218.34 | $213.88 | $215.11 | 2.51M |
| Aug 21, 2026 | $215.58 | $220.25 | $213.46 | $218.85 | 4.7M |
| Aug 20, 2026 | $210.12 | $220.67 | $208.21 | $215.91 | 5.5M |
| Aug 19, 2026 | $203.10 | $212.19 | $202.905 | $211.50 | 5.25M |
| Aug 18, 2026 | $203.97 | $204.23 | $199.49 | $199.58 | 2.29M |
| Aug 17, 2026 | $199.99 | $203.43 | $199.99 | $202.63 | 2.98M |
| Aug 14, 2026 | $203.00 | $203.96 | $201.12 | $202.45 | 2.24M |
| Aug 13, 2026 | $207.06 | $207.4899 | $202.17 | $203.89 | 1.92M |
| Aug 12, 2026 | $204.55 | $207.59 | $202.00 | $205.79 | 3.04M |
| Aug 11, 2026 | $208.05 | $208.44 | $206.0901 | $207.44 | 2.47M |
| Aug 10, 2026 | $203.26 | $209.37 | $200.78 | $209.37 | 3.68M |
| Aug 7, 2026 | $199.40 | $205.19 | $198.435 | $204.76 | 3.32M |
| Aug 6, 2026 | $199.96 | $201.3425 | $196.48 | $199.98 | 2.79M |
Latest DHR news
The latest Smart Investors Daily articles mentioning DHR.
Stock researchCompany · Overview
DHR research
Overview
Company profile and research snapshot.
Company profile
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $249.71
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 22, 2026 | RBC Capital | Outperform | — |
| Jul 22, 2026 | Guggenheim | Buy | — |
| Jul 22, 2026 | Stifel | Buy | — |
| Jul 22, 2026 | TD Cowen | Buy | — |
| Jul 22, 2026 | Wells Fargo | Equal-Weight | — |
News briefing
Generated Sep 4, 2026, 3:08 PM
Why Is DHR Down Today?
Danaher Corporation (DHR) declined 2.14% today, trading near fair value despite maintaining a notable earnings premium relative to peers. While the stock faces near-term selling pressure, recent coverage highlights the company's strategic positioning in artificial intelligence integration across its life sciences and diagnostics divisions.
Bottom line: Danaher's 2.14% decline appears to be tactical rather than thematic, with the company well-positioned for AI-driven growth but trading at an earnings premium that limits near-term upside. Investors should monitor quarterly results for evidence that AI integration is translating to revenue growth and margin expansion while watching for execution risks that could justify the current valuation.
Yahoo · Sep 3, 2026
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 3, 2026
Danaher (DHR) Seen Deftly Navigating AI Integration
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]
Yahoo · Sep 3, 2026
Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development at Global Scale
Genedata, the leading provider of enterprise software for biopharmaceutical R&D, today announced an expanded collaboration with Abcam, a global provider of validated antibodies and assay solutions. By deploying Genedata Biologics® across Abcam's global R&D organization, the two Danaher companies are working together to strengthen antibody development capabilities, unlock the value of scientific data, and accelerate AI-enabled innovation.
AI research layers
Interpretive context generated from the platform’s current data sources.
Danaher Corporation Stock Performance
Danaher Corporation shares closed at $210.96, declining 1.12% in the most recent session, per SID market data. Despite the daily pullback, DHR has demonstrated strong short- and medium-term momentum, gaining 7.77% over the past month and 17.87% over the trailing three months. However, the stock remains down 7.22% on a one-year basis, reflecting lingering headwinds in the life sciences and diagnostics sectors. Technically, DHR trades above both its 50-day moving average of $200.90 and its 200-day moving average of $200.22, according to Massive/Polygon data, suggesting a constructive intermediate-term trend. The 14-day RSI reads 57.2, positioning the stock in neutral territory without overbought or oversold signals. Average daily volume stands at approximately 4.18 million shares. Danaher's beta of 0.923 indicates slightly lower volatility relative to the broader market, consistent with its defensive healthcare sector classification and its current market capitalization of approximately $166.5 billion.
Danaher Corporation Valuation Analysis
Danaher Corporation currently trades at a price-to-earnings ratio of 47.14, a notably elevated multiple that reflects the market's expectation for earnings recovery following the post-pandemic normalization in its bioprocessing and diagnostics businesses, per SID market data. The PEG ratio stands at 14.87, indicating the premium valuation is not well supported by near-term earnings growth rates according to current projections. DHR's price-to-book ratio is 3.23, which aligns with the capital-light, high-margin business models typical within its portfolio of life sciences and diagnostics platforms. The company offers a modest dividend yield of approximately 0.53%, per SEC filings, reflecting management's preference for capital allocation toward acquisitions and reinvestment over shareholder distributions. Within the healthcare sector, Danaher's valuation premium persists as investors price in its Danaher Business System-driven margin expansion potential and its portfolio of recurring revenue streams across bioprocessing, genomics, and water quality end markets.
Smart Money Activity for DHR
Danaher Corporation registers a smart money score of 51 out of 100, reflecting a neutral overall signal per SID market data. The institutional component scores a perfect 25 out of 25, indicating maximum institutional investor confidence and robust fund-level accumulation in the stock. In contrast, insider activity scores just 4.9 out of 25 despite a notably bullish transaction pattern — SEC Form 4 filings reveal 20 insider trades over the past 90 days, with 17 purchases versus only 3 sales. This lopsided buy-to-sell ratio suggests insiders view current price levels favorably, though the low composite insider score may reflect modest dollar volumes relative to outstanding shares. Dark pool activity scores 8.5 out of 25, suggesting limited off-exchange accumulation pressure, according to 13F institutional filings and trade reporting data. Congressional trading activity registers at 12.8 out of 25, indicating moderate legislative portfolio exposure to DHR. The divergence between strong institutional conviction and muted dark pool signals warrants continued monitoring.
Danaher Corporation Earnings Outlook
Danaher Corporation has delivered consecutive earnings beats across its three most recently reported quarters, according to company earnings reports. In the most recent quarter, DHR posted earnings per share of $1.94 against a consensus estimate of $1.84, representing a $0.10 positive surprise. The prior quarter saw EPS of $2.06 versus estimates of $1.94, a $0.12 beat, while the quarter before that produced $2.23 against the $2.17 consensus, a $0.06 upside surprise. This consistent pattern of outperformance suggests management has effectively navigated the bioprocessing demand recovery and maintained cost discipline through the Danaher Business System. Looking ahead, analyst estimates project EPS of approximately $2.17 for the upcoming reporting period, per consensus data. The sequential decline in estimates from $2.23 to $2.17 reflects typical seasonality patterns in the life sciences end markets. Investors will closely monitor bioprocessing order trends and China-related demand dynamics in the next report.
Wall Street Analyst Ratings for DHR
Wall Street consensus on Danaher Corporation remains broadly constructive, with the majority of recent analyst updates reiterating positive ratings, per SID consensus data. On July 22, 2026, four of five covering analysts maintained bullish stances: Guggenheim, Stifel, and TD Cowen each reiterated Buy ratings, while RBC Capital maintained its Outperform designation, according to Wall Street analyst reports. Wells Fargo was the sole neutral voice, reiterating its Equal-Weight rating on the same date. The simultaneous issuance of five ratings on a single day aligns with DHR's most recent earnings release, reflecting updated post-results assessments. The 4-to-1 ratio of bullish-to-neutral ratings underscores broad institutional confidence in Danaher's multi-year recovery thesis across bioprocessing, genomics, and diagnostics. No analyst issued a Sell or Underperform rating in the most recent coverage cycle. The clustering of reiterations rather than upgrades suggests the recent earnings beat was largely in line with buy-side expectations despite exceeding published consensus estimates.
